The present application relates to a drug delivery ocular implant (53) comprising an outer shell (54) having a proximal end (52) and a distal end (50), the outer shell being shaped to define an interior space (58). The implant further comprises at least a first drug (62) positioned within the interior space, a region of drug release (56) at the proximal end of the outer shell (54) and a retention protrusion (359) on the distal end of the outer shell (54). The retention protrusion (359) is configured to anchor the ocular implant (53) at a target tissue site in the eye. The implant further comprises at least one fluid inflow pathway (38k) and one fluid outflow pathway (56k) positioned adjacent the distal end of the outer shell (54), such that the at least one fluid outflow pathway (56k) and the at least one fluid inflow path (38k) is configured to allow ocular fluid to be directed through the implant (53) from an anterior chamber to a physiological outflow space.
